PMID- 25647308
OWN - NLM
STAT- MEDLINE
DCOM- 20151201
LR  - 20181202
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 35
IP  - 4
DP  - 2015 Apr
TI  - Transplantation of human umbilical cord-derived mesenchymal stems cells for the 
      treatment of Becker muscular dystrophy in affected pedigree members.
PG  - 1051-7
LID - 10.3892/ijmm.2015.2084 [doi]
AB  - The regeneration of muscle tissue has been achieved using multipotent mesenchymal 
      stem cells in mouse models of injured skeletal muscle. In the present study, the 
      utility of multipotent human umbilical cord-derived mesenchymal stem cells 
      (hUC-MSCs) in the treatment of Becker muscular dystrophy (BMD), a genetic disease 
      where muscle tissue fails to regenerate, was examined in members from a pedigree 
      affected by BMD. The disease status was evaluated in 4 affected pedigree members 
      (II1, II2, II3 and III2; aged 50, 46, 42 and 6 years, respectively). The 
      transplantation of the hUC‑MSCs (performed on 3 patients, I2, II3 and III2) was 
      performed by infusion with an intravenous drip over a 30‑min period, and the 
      patients were evaluated at 1, 3, 4 and 12 weeks following the procedure. The 
      evaluation was based on physical characteristics, as well as on molecular testing 
      for serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels and a 
      histological examination of muscle biopsies. The patients suffered no adverse 
      reactions in response to the transplantation of the hUC‑MSCs. At 1 week following 
      transplantation all 3 patients showed improvement in the muscle force of the 
      limbs, muscle size and daily activity. The walking gait of patient III2 had 
      improved by 1 week post-transplantation and reached a normal status by 12 weeks. 
      Serum CK and LDH levels were decreased relative to the baseline levels. A 
      histological examination of muscle biopsies displayed no obvious tissue 
      regeneration. In conclusion, the treatment of patients with BMD using hUC-MSCs 
      was safe and of therapeutic benefit that lasted for up to 12 weeks. hUC-MSCs are, 
      therefore, a potential cell therapy-based treatment option for patients with 
      muscular dystrophies.
FAU - Li, Pang
AU  - Li P
AD  - Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 
      250011, P.R. China.
FAU - Cui, Kai
AU  - Cui K
AD  - Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 
      250011, P.R. China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 
      250011, P.R. China.
FAU - Wang, Zhendan
AU  - Wang Z
AD  - Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 
      250011, P.R. China.
FAU - Shen, Yangyang
AU  - Shen Y
AD  - Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 
      250011, P.R. China.
FAU - Wang, Xiangyu
AU  - Wang X
AD  - Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 
      250011, P.R. China.
FAU - Zhang, Jianbo
AU  - Zhang J
AD  - Department of Pathology, Shandong Cancer Hospital, Jinan, Shandong 250011, P.R. 
      China.
FAU - Tong, Feng
AU  - Tong F
AD  - The Dean's Office, Shandong Cancer Hospital, Jinan, Shandong 250011, P.R. China.
FAU - Li, Sheng
AU  - Li S
AD  - Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 
      250011, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20150130
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 2.7.3.2 (Creatine Kinase)
SB  - IM
MH  - Adolescent
MH  - Biopsy
MH  - Child
MH  - Creatine Kinase/blood
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*cytology
MH  - Muscle Strength
MH  - Muscle, Skeletal/metabolism/pathology
MH  - Muscular Dystrophy, Duchenne/blood/diagnosis/metabolism/*therapy
MH  - *Pedigree
MH  - Time Factors
MH  - Treatment Outcome
MH  - Umbilical Cord/*cytology
EDAT- 2015/02/04 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/02/04 06:00
PHST- 2014/09/12 00:00 [received]
PHST- 2015/01/20 00:00 [accepted]
PHST- 2015/02/04 06:00 [entrez]
PHST- 2015/02/04 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.3892/ijmm.2015.2084 [doi]
PST - ppublish
SO  - Int J Mol Med. 2015 Apr;35(4):1051-7. doi: 10.3892/ijmm.2015.2084. Epub 2015 Jan 
      30.